Forum Pharmaceuticals shut down a few weeks ago, and now one of its top executives has resurfaced at a new company. Gerhard Koenig, Forum’s former chief scientific officer and head of research, has been named the CEO of Cambridge, MA-based Quartet Medicine, a startup developing pain drugs. Merck, in January, grabbed an exclusive option to buy Quartet at a later date. The startup’s founding CEO, former Atlas Venture venture partner Kevin Pojasek, is now the head of portfolio strategy at U.K.-based Immunocore, according to LinkedIn.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler